Key result
Ambulatory levosimendan in advanced HFrEF is linked to significant GDMT uptitration at one year.
Why the study?
It was unclear whether intermittent ambulatory levosimendan infusions could facilitate the titration of guideline-directed medical therapy in patients with advanced HFrEF intolerant to target doses.
Do intermittent ambulatory levosimendan infusions improve the uptitration of guideline-directed medical therapy in patients with advanced HFrEF?
Population
37 patients with advanced HFrEF
Comparison
Repeated ambulatory infusions of levosimendan
Design
Single-center prospective study
Follow-up
1 year
Authors
Loading...
May aid GDMT uptitration in advanced HFrEF; leaves open causality and needs RCTs before adoption.
Observational (n=37)
No
Do intermittent ambulatory levosimendan infusions improve the uptitration of guideline-directed medical therapy in patients with advanced HFrEF?
Intermittent ambulatory levosimendan infusions may facilitate the uptitration of guideline-directed medical therapy and reduction of diuretic doses in patients with advanced HFrEF.
Masarone et al. (2022) conducted an observational in Advanced heart failure with reduced ejection fraction (HFrEF) (n=37). Intermittent ambulatory levosimendan infusions vs. Baseline was evaluated on Uptitration of disease-modifying drugs (guideline-directed medical therapy). Ambulatory levosimendan infusions in advanced HFrEF patients increased bisoprolol doses from 3.2 to 5.9 mg (p=0.02) and sacubitril/valsartan from 41.67 to 68.5 mg (p=0.01) at 1 year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: